Literature DB >> 31876751

Association between continuity of care and type 2 diabetes development among patients with thyroid disorder.

Sang Ah Lee1,2,3, Dong-Woo Choi1,2, Junhyun Kwon1,2, Doo Woong Lee1,2, Eun-Cheol Park2,4.   

Abstract

Thyroid disorders are associated with blood glucose abnormalities. For rendering the patients euthyroid, routine screening and care are essential. Therefore, the aim of this study was to investigate the association between continuity of care (COC) and type 2 diabetes onset among patients with thyroid disorders.We used the national claim data. Our study population was 4099 patients with hyperthyroidism or hypothyroidism. For calculating COC, the Most Frequent Provider Continuity Index (MFPCI), Modified Modified Continuity Index (MMCI), and COC Index (COCI) were used. The dependent variable was type 2 diabetes onset. The Cox proportional hazard regression model was used.Among 4099 patients with thyroid disorders, 25.3% experienced onset of type 2 diabetes. Thyroid patients who had MFPCI and COCI below the median were more likely to experience onset of type 2 diabetes than who had these indices above the median (MFPCI: hazard ratio [HR] = 1.26, 95% confidence interval [CI] = 1.09-1.46; COCI: HR = 1.22, 95% CI = 1.06-1.41). Our subgroup analysis showed that female patients and those 20 to 34 years of age showed a significant association between COC and onset of type 2 diabetes.Patients with thyroid disorders with low COC showed an increased risk of developing type 2 diabetes. Therefore, efforts to enhance COC among patients with thyroid disorders needs to be encouraged.

Entities:  

Mesh:

Year:  2019        PMID: 31876751      PMCID: PMC6946430          DOI: 10.1097/MD.0000000000018537

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Thyroid dysfunction is one of the most prevalent endocrine disorders. According to the American Association of Clinical Endocrinologists, an estimated 13 million people, representing 4.8% of the population of the United States, have undiagnosed thyroid dysfunction. The prevalence of thyroid dysfunction is on the rise in South Korea. According to the Health Insurance Review and Assessment Service, the number of people with thyroid dysfunction has increased from 914,000 in 2009 to 1,264,000 in 2016. Along with this trend, comorbidities including heart failure, atrial fibrillation, cardiovascular diseases, depression, and metabolic disorders have also increased. Previous studies have focused on the relationship between thyroid dysfunction and diabetes.[,,,,] Thyroid dysfunction and diabetes are the two most common endocrine system disorders. Furthermore, these two diseases are closely related,[,,,,] as evidenced by the term “thyroid diabetes.”[,,,,,,] Previous studies have studied the relationship between thyroid hormone and blood glucose. According to these studies, hyperthyroidism is related to hyperglycemia as a result of increased glucose gut absorption owing to the excess thyroid hormones. In addition, increased proinsulin levels are observed in untreated Graves’ disease. Hypothyroidism can also be related to decreased glucose intolerance and insulin sensitivity.[,] Moreover, it has been reported that hypothyroidism is associated with metabolic syndrome and could be indirectly related to the diabetes onset. Insulin and glucose status may also be unstable owing to the effect of abnormal thyroid hormone levels.[,,] Therefore, controlling thyroid hormones is imperative to prevent the onset of diabetes among patients with thyroid dysfunction. According to the previous study, appropriate timely treatment along with routine screening programs could prevent negative outcomes. In this respect, continuity of care (COC) could be one of the appropriate methods to control a patient's thyroid hormone status and monitor the onset of complications. COC means a continuous relationship between physicians and patients. A high level of COC has been associated with positive outcomes including better quality of care, treatment adherence, and improved self-management. Particularly, this concept is important for patients with chronic disease because it can prevent sudden aggravation of the condition. Although COC is an important concept for patients with chronic diseases, there are few studies on the outcome of COC in patients with thyroid dysfunction. Therefore, this study aimed to investigate the association between COC and onset of type 2 diabetes (T2D) among patients with thyroid dysfunction in South Korea using nationwide claim data. We hypothesized that patients with thyroid dysfunction along with low COC are more likely to experience onset of T2D.

Methods

Data and study population

We used the Korean National Health Insurance claims database from 2002 to 2013, which includes the claims data of 1,025,340 individuals, accounting for 2% of the South Korean population. The cohort population was selected using random sampling methods. This data is secondary data and does not contain any data which can identify individual. Therefore, ethical approval is exempted. The requirement for informed consent was waived because this study was based on routinely collected claims data. Our study population included those who visited medical institutions with thyroid disorders (International Classification of Disease [ICD] codes E01–03, hypothyroidism, and E05, hyperthyroidism). To calculate COC, we excluded those who visited medical institutions fewer than four times during 2 years from the onset of their thyroid disorder diagnosis. Additionally, we also excluded those whose onset of thyroid disorder year was in 2012 or 2013, in consideration of the follow-up time. Therefore, the final study population included 4099 patients with thyroid disorders.

Variables

We used three indices for measuring COC. First, the Most Frequent Provider Continuity Index (MFPCI) measures the frequency of visits to the most frequent provider. Second, the Modified Modified Continuity Index (MMCI) measures not only the total number of visits to medical institutions but also the total number of providers available. This index reflects the number and distribution of visits to other providers. Third, the COC Index (COCI) integrates both the MFPCI and MMCI. The COCI measures an individual's COC while considering the effect of the total number of providers and total number of visits. where N is the total number of visits, n is the number of visits to provider i, M is the total number of providers. Our dependent variable is T2D onset. Patients who visited a medical institution and were diagnosed with T2D (ICD-10 code E11) after 2 years from the onset of a thyroid disorder were classified into the T2D onset group. Patients with no record of T2D were classified into the non-onset group. We controlled for age, sex, income, insurance type, residential area, type of thyroid disorder, Charlson Comorbidity Index, presence of a disability, type and location of main attending clinic, and thyroid disorder onset year. Age was classified into four groups (20–34, 35–54, 55–64, and ≥65 years). As the data do not contain exact income, health insurance premiums were used to estimate income based on three categories (low; the bottom 20% of premiums; middle; 20% to 80% of premiums, high; the top 20% of premiums). Residential area was classified into capital area, metropolitan area, and rural area. The type of thyroid disorder was classified as hypothyroidism (ICD-10 codes E01-E03) or hyperthyroidism (ICD-10 code E05). The type of main attending clinic was classified as general hospital, hospital, or clinic. The location of the main attending clinic was categorized the same as the residential area.

Statistical analysis

The chi-squared test and Student's t test were used to examine the general characteristics of the study population. To investigate the association between COC and onset of T2D among patients with thyroid disorders, Cox proportional hazards model was used to calculate hazard ratios (HRs) by adjusting for control variables. We also conducted a set of subgroup analyses stratified by age, sex, income, and type of thyroid disorder. All statistical analyses were conducted using SAS software (version 9.4; SAS, Cary, NC). Statistical significance was set at P < .05.

Results

Table 1 shows the general characteristics of the study population. Among 4099 patients with thyroid disorders, 1036 (25.3%) experienced an onset of T2D. The mean MFPCI, MMCI, and COCI were 0.897 ± 0.165, 0.940 ± 0.105, and 0.842 ± 0.235, respectively. Among those whose MFPCI, MMCI, and COCI were less than the median, 29.3% (n = 250), 27.3% (n = 330), and 28.9% (n = 330) experienced T2D, respectively.
Table 1

General characteristics of the study population.

General characteristics of the study population. Table 2 shows the association between COC indices and onset of T2D. Thyroid patients with their MFPCI and COCI less than the median were more likely to experience an onset of T2D than were those with values exceeding the median (MFPCI: HR = 1.26, 95% CI = 1.09–1.46; COCI: HR = 1.22, 95% CI = 1.06–1.41). MMCI did not show a statistically significant association; however, those with values below the median had a higher HR (HR = 1.14, 95% CI = 1.00–1.30), the same as the other indices.
Table 2

Association between continuity of care indices and onset of type 2 diabetes∗.

Association between continuity of care indices and onset of type 2 diabetes∗. Table 3 shows the results of a set of subgroup analyses stratified by type of thyroid disorder, income, age group, and sex. Both hypothyroidism (HR = 1.31, P = .0160) and hyperthyroidism (HR = 1.23, P = .0405) showed a significant association with the onset of T2D when the MFPCI was below the median. Only hypothyroidism showed a statistically significant association with onset of T2D when the COCI was below the median (HR = 1.27, P = .0284). Regarding income, the higher income group did not show any association of COC and onset of T2D. Regarding age group, only the 20 to 34 age group showed an association with onset of T2D for MFPCI (HR = 1.34, P = .0237), MMCI (HR = 1.30, P = .0342), and COCI (HR = 1.31, P = .0330) values below the median. Considering sex, female patients showed a significant association with diabetes onset when their COCI was below the median COC, whereas male patients did not show any association.
Table 3

Association between continuity of care indices and onset of type 2 diabetes stratified by type of thyroid disorder, income, age, and sex∗.

Association between continuity of care indices and onset of type 2 diabetes stratified by type of thyroid disorder, income, age, and sex∗.

Discussion

In this study, we aimed to examine the association between diverse COC indices including MFPCI, MMCI, and COCI and onset of T2D among patients with thyroid dysfunction. The result of this study is in line with the results of previous studies that evaluated the effect of COC on health outcomes.[,,] While limited studies have previously evaluated the effect of COC in patients with thyroid dysfunction, our study showed that patients having thyroid dysfunction with low COC were more likely to experience onset of T2D, and this association was generally maintained for all three indices (MFPCI, MMCI, and COCI). Regarding subgroup analysis, this association was also observed regardless of the type of thyroid dysfunction (hyperthyroidism or hypothyroidism). Additionally, female patients and patients aged 20 to 34 years showed a significant association between COC and onset of T2D. The association between abnormal thyroid hormone levels and diabetes has been studied for several decades, and many studies have shown such an association.[,,,] A point of similarity is that abnormal thyroid hormone levels increased the risk of developing diabetes.[,] Hyperthyroidism has been related to increase in liver gluconeogenesis, increased peripheral insulin resistance, and it showed an association with glucose intolerance.[,] Hypothyroidism has also been found to be associated with decreased glucose intolerance and peripheral insulin sensitivity,[,] and improved insulin sensitivity was observed with treatment of hypothyroidism. Furthermore, a previous study reported that hypothyroidism was associated with metabolic syndrome and could be related to diabetes onset, indirectly. Therefore, controlling thyroid hormones levels within the normal range is imperative in patients with thyroid dysfunction to prevent the development of diabetes. For treating hyperthyroidism, the production and secretion of stimulant-autoantibody about the TSH receptor should be suppressed. Thus, anti-thyroid medications that suppress the production and secretion of thyroid hormone are used to maintain normal thyroid function. According to the diagnosis and treatment guideline of thyroid disorders,[,] 97.1% of endocrinologists in Korea use medications (e.g., antihyperthyroid medication) as the initial treatment. The main reason of treatment failure is non-adherence to medication, and thus, regular follow-up is important. The guideline recommends conducting follow-up 4 weeks after the first intake of medication, with 4 to 8 weeks of follow-up until normal state is achieved. The response to treatment is assessed based on free T4 and T3 or TSH levels. A similar treatment process is followed for hypothyroidism as well. For patients with hypothyroidism, supplement of thyroid hormone is needed. Intake of thyroid hormone supplement is similar to normal thyroid hormone secretion and involves similar mechanisms, in which thyroid hormone is secreted as T4 and converted to T3. Therefore, maintaining TSH or FT4 in the normal range is the target of treatment. Hypothyroidism requires follow-up 4 to 6 weeks after taking thyroid hormone, with continuous follow-up for about 6 to 12 months. Thus, COC is important in the follow-up period. If patients go to another physician without their medical records, the treatment process could be mixed up. Therefore, low COC could influence thyroid function. In summary, low COC makes it difficult to follow up the change in thyroid function according to the treatment. In this process, considering its well-known benefits, COC could contribute to normalizing thyroid hormone levels. COC is related to better outcomes of care owing to several positive effects. From the perspective of physicians, they can obtain better knowledge about their patients and detect possible problems sooner[,] because they can provide treatment continuously and do not have to check their status from the beginning. In terms of patients, those with high COC have high trust in their physicians, which is potentially related to their medication or treatment compliance. Furthermore, patients with high COC have a tendency to show better self-management behaviors based on this trust. Considering that an unstable thyroid hormone status could impair glucose control, maintaining consistent treatment is necessary to stabilize the thyroid hormones. Maintaining stable levels of thyroid hormones may help in avoiding unstable blood glucose control. According to the treatment guidelines for patients with thyroid disorders, periodic monitoring is imperative for judging the response to treatment and controlling the dosage of medication according to the patient's status. In addition, monitoring a newly diagnosed patient's status regularly until their status becomes stable is recommended. Therefore, the concept of COC is needed. By regularly following up the thyroid hormone status and administering proper treatment for the patient's condition, thyroid hormones can be well managed. Our subgroup analysis showed that patients in the low- or middle-income group and the young adult group as well as female patients showed an increased risk of developing diabetes when their COC indices were low. In the high-income group, there was no statistically significant association. Generally, low socioeconomic groups lack social networks that provide much information about disease. Therefore, visiting physicians regularly is important to obtain knowledge about management of their disease or other information. Young adults have a relatively low risk of developing diabetes, and diabetes often occurs in middle-aged or older individuals. However, in this study, patients with thyroid disorders in the 20 to 34 age group showed a higher rate of diabetes when they had a low COCI. Therefore, COC should be carefully considered especially in young adults. The results of this study should be interpreted carefully owing to several limitations. First, this study used claims data, and the accuracy of such data has been controversial for several years because the original purpose of these data was for claiming instead of research. However, a study on the accuracy of these data showed almost 70% accuracy. Second, these data did not contain information about the severity of the diabetes and thyroid disorders. Furthermore, the level of thyroid hormone or blood glucose cannot be investigated because the data did not contain lab information. In addition, other factors such as personal lifestyle behaviors such as smoking, drinking, or physical activities, which could affect the development of diabetes were not available. This lack of information could generate a potential confounding bias. Third, although we washed out the first year of the cohort study by extracting newly diagnosed patients with thyroid dysfunction, there could be contamination because there were no data before 2002. Fourth, the physicians who provided medical services could not be identified. Thus, we calculated COC based on medical institutions. However, a strength of this study is the investigation of the association between thyroid disorders and diabetes by adopting the COC concept.

Conclusion

Considering the increasing prevalence of thyroid disorders in Korea, additional attention must be paid to the problems resulting from thyroid disorders. Considering the relationship between thyroid disorders and diabetes, an effort to minimize the effect of thyroid disorders on the development of T2D is needed. According to the results of this study, which found that patients with thyroid disorders with low COC showed an increased risk of developing T2D, efforts to enhance COC for patients with thyroid disorders should be encouraged. Further study should be conducted by using laboratory data, and the differences in thyroid hormone levels according to COC levels should be investigated.

Author contributions

Conceptualization: Sang Ah Lee. Formal analysis: Dong-Woo Choi. Methodology: Junhyun Kwon. Supervision: Eun-Cheol Park. Writing – original draft: Sang Ah Lee. Writing – review & editing: Doo Woong Lee. Eun-Cheol Park: 0000-0002-2306-5398. Eun-Cheol Park orcid: 0000-0002-2306-5398.
  32 in total

1.  Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study.

Authors:  Nicolas Rodondi; Douglas C Bauer; Anne R Cappola; Jacques Cornuz; John Robbins; Linda P Fried; Paul W Ladenson; Eric Vittinghoff; John S Gottdiener; Anne B Newman
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

2.  Is having a regular provider of diabetes care related to intensity of care and glycemic control?

Authors:  P J O'Connor; J Desai; W A Rush; L M Cherney; L I Solberg; D B Bishop
Journal:  J Fam Pract       Date:  1998-10       Impact factor: 0.493

3.  Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance.

Authors:  D S Cooper
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

Review 4.  Thyroid hormones and the metabolic syndrome.

Authors:  K Alexander Iwen; Erich Schröder; Georg Brabant
Journal:  Eur Thyroid J       Date:  2013-05-28

Review 5.  The interface between thyroid and diabetes mellitus.

Authors:  Leonidas H Duntas; Jacques Orgiazzi; Georg Brabant
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

6.  Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism.

Authors:  C Rochon; I Tauveron; C Dejax; P Benoit; P Capitan; A Fabricio; C Berry; C Champredon; P Thieblot; J Grizard
Journal:  Clin Sci (Lond)       Date:  2003-01       Impact factor: 6.124

7.  Does higher continuity of family physician care reduce hospitalizations in elderly people with diabetes?

Authors:  John C Knight; Jeffrey J Dowden; Graham J Worrall; Veerabhadra G Gadag; Madonna M Murphy
Journal:  Popul Health Manag       Date:  2009-04       Impact factor: 2.459

8.  Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans.

Authors:  G Dimitriadis; B Baker; H Marsh; L Mandarino; R Rizza; R Bergman; M Haymond; J Gerich
Journal:  Am J Physiol       Date:  1985-05

9.  Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.

Authors:  Jeffrey R Garber; Rhoda H Cobin; Hossein Gharib; James V Hennessey; Irwin Klein; Jeffrey I Mechanick; Rachel Pessah-Pollack; Peter A Singer; Kenneth A Woeber
Journal:  Thyroid       Date:  2012-11-06       Impact factor: 6.568

10.  Thyroid disorders and diabetes mellitus.

Authors:  Mirella Hage; Mira S Zantout; Sami T Azar
Journal:  J Thyroid Res       Date:  2011-07-12
View more
  3 in total

1.  Continuity of Care Is Associated with Medical Costs and Inpatient Days in Children with Cerebral Palsy.

Authors:  Kuang-Tsu Yang; Chun-Hao Yin; Yao-Min Hung; Shih-Ju Huang; Ching-Chih Lee; Tsu-Jen Kuo
Journal:  Int J Environ Res Public Health       Date:  2020-04-23       Impact factor: 3.390

2.  Interleukin-8, CXCL10, CXCL11 and their role in insulin resistance in adult females with subclinical hypothyroidism and prediabetes.

Authors:  Roxana Adriana Stoica; Nicoleta Drăgana; Robert Ancuceanu; Ovidiu Ionuț Geicu; Cristian Guja; Anca Pantea-Stoian; Damaris-Cristina Gheorghe; Raluca-Ioana Stefan-van Staden; Cristian Serafinceanu; Adrian Costache; Constantin Ionescu-Tîrgoviște
Journal:  J Clin Transl Endocrinol       Date:  2022-04-06

3.  Phytochemical Profiling in Conjunction with In Vitro and In Silico Studies to Identify Human α-Amylase Inhibitors in Leucaena leucocephala (Lam.) De Wit for the Treatment of Diabetes Mellitus.

Authors:  Senthil Renganathan; Sakthivel Manokaran; Preethi Vasanthakumar; Usha Singaravelu; Pok-Son Kim; Arne Kutzner; Klaus Heese
Journal:  ACS Omega       Date:  2021-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.